Importance & Scope:
The Bioavailability Bioequivalence Research Center aims to become a regional center of excellence for assuring the safety and efficacy of generic pharmaceutical products for human use. 5 Bioavailability refers to the extent to which a drug is absorbed into the body and is thus available to act upon the drug's intended target, also known as the "site of action. Bioavailability and Bioequivalence Studies Submitted in New Drug Applications or Investigational New Drug Applications-also known as the NDA BA and BE.
Play a key role in the drug development period for both new drug products and their generic equivalents. These studies are also important in the post approval period in the presence of certain manufacturing changes. Information in the overall set of data that ensure the availability of safe and effective medicines to patients and practitioners. BA/BE studies has been determined to have practical and public health value for pharmaceutical sponsors, for regulatory agencies, and for patients and practitioners.
BABE-2015 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Bioavailability and Bioequivalence Studies. It also provides the chance for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the fields of Bioavailability and Bioequivalence.BABE-2015 is an international platform for presenting research about Bioavailability and Bioequivalence studies, exchanging ideas about it and thus, contributes to the dissemination of knowledge for the benefit of both the academia and business. BABE-2015 is where the future of Bioavailability and Bioequivalence intersects.
Chicago, a city in the U.S. state of Illinois, is the third most populous city in the United States and the most populous city in the American Midwest, with approximately 2.7 million residents. Its metropolitan area (also called "Chicagoland"), which extends into Indiana and Wisconsin, is the third-largest in the United States, after those of New York City and Los Angeles, with an estimated 9.8 million people. Chicago is the county seat of Cook County, though a small portion of the city limits also extends into DuPage County.
Chicago was incorporated as a city in 1837, near a portage between the Great Lakes and the Mississippi River watershed. Today, Chicago is listed as an alpha+ global city by the Globalization and World Cities Research Network, and ranks seventh in the world in the 2012 Global Cities Index. The city is an international hub for finance, commerce, industry, telecommunications, and transportation, with O'Hare International Airport being the second-busiest airport in the world in terms of traffic movements.
In 2012, Chicago hosted 46.2 million international and domestic visitors. Among metropolitan areas, Chicago has the fourth-largest gross domestic product (GDP) in the world, just behind Tokyo, New York City, and Los Angeles, and ranking ahead of London and Paris. Chicago is one of the most important Worldwide Centers of Commerce and trade.
Chicago's notability has found expression in numerous forms of popular culture, including novels, plays, films, and songs. The city has many nicknames, which reflect the impressions and opinions about historical and contemporary Chicago. The best-known include "Windy City" and "Second City.
- Emerging Bioavailability and Bioequivalence Studies
- Bioanalytical Methodology
- Contemporary Challenges of Drug Design, Discovery and Development
- Bioavailability, Bioequivalence and drug product selection
- Metabolic pathways and changes in Nutrient Bioavailability
- Clinical pharmacology and Therapeutics
- Translational Cancer Research and Anticancer Drug Discovery.
- Chronopharmaceutics: Germane Approach to Drug Delivery
- Neutraceuticals Bioequivalence Study
Why to attend???
With members from around the world focused on learning about Bioavailability and Bioequivalence studies. OMICS Group Conferences deliver new ideas, convictions, strategies, and tactics that directly affect how you do business. No other event will offer a more impressive roster of keynote speakers, quality attendees and compelling content.This Conference will provide a forum for exchange of ideas and authoritative views by leading scientists as well as business leaders and investors in this exciting field. Outstanding keynote speakers and well known leading scientists and experts from around the globe will be expected to share their knowledge.BABE-2015 stands for advertising of the products/services of the companies in the Medical and Healthcare sectors shall be placed in the exhibition area throughout the Conference.
A Unique Opportunity for Advertisers and Sponsors at this International event:
Major related Associations around the Globe
- Association of Clinical Research Organization (ACRO)
- APHETA Institute of Clinical Research
- European CRO Federation – EUCROF
- The Canadian Generic Pharmaceutical Association (CGPA)
- Canadian Drug Manufacturers Association
- Nonprescription Drug Manufacturers Association of Canada
- Pharmaceutical Manufacturers Association of Canada
- Industrial Biotechnology Association of Canada
- Medicines Control Council (MCC)
- Canadian Homeopathic Pharmaceutical Association
- National Association of Pharmacy Regulatory Authorites
- Nuclear Medicine Alliance
- The Canadian Pharmaceutical Association
- Central Drugs Standard Control Organization
Major related Associations in USA
Statistical Analysis of Associations
Figure 1: Statistical Analysis
Pharmaceutical backgrounds, Health Care institutions, Pharmaceutical regulatory agencies, Clinical Research organizations, Generic Drug, Regulatory Affairs, Drug Formulation Research and Techniques, Drug Evaluation and Research, Clinical Therapeutics, ADME Properties, Drug Dissolution, On Site Drug Delivery, Drug Absorption, New Drug Application (NDA), Investigation of New Drug Application (INDA)
Companies Associated with Generic Drugs & CROs
Figure 2: Generic Drugs & CRO Companies
Worldwide total generic prescription drug revenue from 2006 to 2020(in billion U.S. dollars)
This statistic depicts the total generic prescription drug revenue worldwide from 2006 to 2020. In 2018, the industry is expected to generate 96 billion U.S. dollars in generic prescription drug revenue worldwide. This statistic includes the leading 500 pharmaceutical and biotechnology companies
Figure 3: Generic prescription drug revenue worldwide
Glance at Market Generic Drugs:
The global market for generic drugs was worth $81 billion in 2008, $84 billion in 2009, estimated to be $168.7 billion in 2014. Sales of U.S. generic drugs currently dominate the market with $54 billion for the 2014. Japan’s generic drugs market is expected to have the highest rate of growth among major markets at 12.2%, increasing from $5.4 billion in 2009 to $9.6 billion in 2014.
By 2016, it is expected that the value of the total global generics sector will have risen to $358 billion. The North American market is estimated to reach nearly $107 billion in 2016 with an increase of 7.9% compound annual growth rate annual growth rate and Emerging market to reach nearly $115 billion. 4
Figure 4: Global market for Generic Drug
Savings through generic drug usage in the United States from 2002 to 2011 (in billion U.S. dollars)
This statistic depicts savings through generic drug usage in the United States from 2002 to 2011. In 2002, the healthcare system in the United States saved some 60 billion U.S. dollars via the usage of generic drugs.
Figure 5: Generic drug usage